Not Yet RecruitingPhase 3ACTRN12605000028606

Tenofovir versus Adefovir for the treatment of HBeAg positive chronic hepatitis B

A randomised, phase III, double blind study to evaluate the efficacy and safety of tenofovir DF versus adefovir dipivoxil in the treatment of HBeAg positive chronic hepatitis B to suppress viral replication, amend the course of the disease and decrease morbidity.

Sponsor

Gilead Sciences Inc

Enrollment

240 participants

Start Date

Aug 1, 2005

Study Type

Interventional

Conditions

HBeAg positive chronic hepatitis B

Eligibility

Plain Language Summary

Simplified for easier understanding

This study compares tenofovir to adefovir for treating HBeAg-positive chronic hepatitis B. It is for adults aged 18 to 69 with chronic hepatitis B and active viral replication. Participation involves taking daily antiviral medication and regular monitoring including blood tests and possible liver biopsies.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

To compare the efficacy of tenofovir DF 300 mg versus adefovir dipivoxil 10mg over 48 weeks of treatment

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000028606